(Q78179444)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

editorial

0 references

title

Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

author name string

M Cazzola

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

M G Matera

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

publication date

1 April 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

page(s)

227-229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464885%20AND%20SRC:MED&resulttype=core&format=json

The use of bronchodilators in stable chronic obstructive pulmonary disease.

12 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990017-3

7 January 2021